Adamed Pharma was awarded in the prestigious Prix Galien Polska competition

On 19 November, during a ceremonial gala, Adamed Pharma was honored with a prestigious award in the international Prix Galien competition. In the "Best Second Generation Drug" category, Adamed Pharma's Sitagliptin + Metformin XR combination – used in the treatment of type 2 diabetes – was awarded. The award was received on behalf of the company by Dorota Chynowska, Business Unit Director of Adamed Pharma.

The combination of Sitagliptin + Metformin XR by Adamed Pharma, awarded by the jury of the Prix Galien competition, is a combination of two substances used in the treatment of type 2 diabetes. The drug works by combining two therapeutic mechanisms in a synergistic way, thus providing more effective control of blood glucose levels in patients.

Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), which means that it increases the level of incretins, hormones responsible for stimulating the secretion of insulin after a meal and inhibiting the secretion of glucagon. As a result, it supports the functioning of the pancreas in regulating blood sugar levels. Metformin XR (extended-release), on the other hand, works on a different level, improving tissue sensitivity to insulin and inhibiting glucose production in the liver.

The introduction of this combination, unique on a Polish and European scale, gives a wide range of patients access to effective and safe diabetes therapy, while reducing the risk of very common gastrointestinal adverse reactions resulting from the use of immediate-release (IR) metformin. In addition, this combination makes it easier to follow medical recommendations due to the reduction of the frequency of drug dosing (1x daily vs 2x daily), which increases patient comfort. This improves adherence to therapy, which in turn promotes better disease control, reducing the risk of complications associated with type 2 diabetes. As a result, the combination of Sitagliptin with Metformin XR provides a modern, convenient and effective therapeutic option that responds to the needs of patients in diabetes management.

The combination presented by Adamed Pharma won the recognition of the competition jury for its innovation, effectiveness, safety of use, as well as for its positive impact on the quality of life of patients with type 2 diabetes. The Prix Galien medal, awarded to Adamed Pharma in the "Best second-generation drug" category, was received by Dorota Chynowska, Business Unit Director, during the award ceremony.

"I am extremely proud that our work on the Sitagliptin + Metformin XR combination has been recognized in such a prestigious competition as the Prix Galien. This award is not only a recognition of the entire Adamed Pharma team, but also a tribute to innovative therapies that really improve the quality of patients’ lives and respond to the key challenges of modern medicine. This award motivates us to further develop and search for new, breakthrough solutions in the treatment of civilization diseases of the 21st century" says Sylwia Berdzik-Kalarus, Member of the Management Board, Director of Commercial Operations and Business Development, commenting on the award.

"Receiving the Prix Galien award in the category 'Best drug of the second generation' is a great honor for us. This is proof of the importance of the desire to introduce breakthrough and unique innovations in medicine. Our goal is not only to provide effective therapies, but also to change the future of treatment so that patients can live a fuller and healthier life" said Dorota Chynowska Business Unit Director, during the award ceremony.

The Prix Galien is considered in the industry to be the equivalent of the Nobel Prize in Biopharmaceutical Research and the Development of Modern Therapies. The award committee, whose members are eminent personalities from the world of science, attaches particular importance to solutions that improve the quality of life of millions of patients.

The history of the Prix Galien dates back to 1970. The event takes place in 17 countries incl. France, Spain, Portugal, Great Britain, Germany, the Netherlands, Belgium, Luxembourg, Switzerland, Italy, Turkey, Israel, the United States and Canada. In Poland, the award has been present since 2012. Every two years, the Prix Galien winners from each country take part in the International Prix Galien, which recognizes the most important innovations on a global scale.